CMR FigSearch
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Butaye, P.
Right arrow Articles by Haesebrouck, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Butaye, P.
Right arrow Articles by Haesebrouck, F.

Next Article 

Clinical Microbiology Reviews, April 2003, p. 175-188, Vol. 16, No. 2
0893-8512/03/$08.00+0     DOI: 10.1128/CMR.16.2.175-188.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Antimicrobial Growth Promoters Used in Animal Feed: Effects of Less Well Known Antibiotics on Gram-Positive Bacteria

Patrick Butaye,* Luc A. Devriese, and Freddy Haesebrouck

Laboratory of Veterinary Bacteriology and Mycology, Department of Pathology, Bacteriology and Poultry Diseases, Faculty of Veterinary Medicine, University of Ghent, 9820 Merelbeke, Belgium

There are not many data available on antibiotics used solely in animals and almost exclusively for growth promotion. These products include bambermycin, avilamycin, efrotomycin, and the ionophore antibiotics (monensin, salinomycin, narasin, and lasalocid). Information is also scarce for bacitracin used only marginally in human and veterinary medicine and for streptogramin antibiotics. The mechanisms of action of and resistance mechanisms against these antibiotics are described. Special emphasis is given to the prevalence of resistance among gram-positive bacteria isolated from animals and humans. Since no susceptibility breakpoints are available for most of the antibiotics discussed, an alternative approach to the interpretation of MICs is presented. Also, some pharmacokinetic data and information on the influence of these products on the intestinal flora are presented.


* Corresponding author. Present address: VAR-CODA-CERVA, Groeselenberg 99, B1180 Brussels, Belgium. Phone: 32 (0)2 379 04 15. Fax: 32 (0)2 379 06 70. E-mail: pabut{at}var.fgov.be.


Clinical Microbiology Reviews, April 2003, p. 175-188, Vol. 16, No. 2
0893-8512/03/$08.00+0     DOI: 10.1128/CMR.16.2.175-188.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Vaccine Immunol.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2003 by the American Society for Microbiology. All rights reserved.